Moleculin's Annamycin extends survival >60% in metastatic pancreatic cancer preclinical models at AACR 2026

Moleculin Biotech, Inc.

Median survival 29 days vs 18 days (p=0.0003) in metastatic PDAC models.
Significant tumor volume reduction across multiple PDAC models (p<0.001).
Higher tumor/pancreatic accumulation vs doxorubicin (p<0.0001).
Induced CD8+ and CD4+ T-cell infiltration, suggesting immune activation.
No cardiotoxicity observed; supports Annamycin's differentiated safety profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.